The microbiome landscape in pediatric Crohn’s disease and therapeutic implications

References

• Yu YR, Rodriguez JR. Clinical presentation of Crohn’s, ulcerative colitis, and indeterminate colitis: symptoms, extraintestinal manifestations, and disease phenotypes. Semin Pediatr Surg. 2017;26(6):349–23. doi:10.1053/j.sempedsurg.2017.10.003.
   PubMed Web of Science ®Google Scholar
• Rahmani P, Rasti G, Gorgi M, Motamed F, Sharifi P. Extraintestinal manifestation of inflammatory bowel disease and associated factors in pediatric patients. Ann Med Surg. 2022;75(February):103363. doi:10.1016/j.amsu.2022.103363.
   PubMedGoogle Scholar
• Rogler G, Singh A, Kavanaugh A, Rubin DT. Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management. Gastroenterology. 2021;161(4):1118–1132. doi:10.1053/J.GASTRO.2021.07.042.
   PubMed Web of Science ®Google Scholar
• de Laffolie J. Epidemiological research and treatment data analysis for chronic inflammatory bowel diseases: improvement in care of children and adolescents. Monatsschr Kinderheilkd. 2020;168(4):298–313. doi:10.1007/s00112-020-00852-9.
   Web of Science ®Google Scholar
• Øyri SF, Muzes G, Sipos F. Dysbiotic gut microbiome: a key element of Crohn’s disease. Comp Immunol Microbiol Infect Dis. 2015;43:36–49. doi:10.1016/j.cimid.2015.10.005.
   PubMed Web of Science ®Google Scholar
• Tiffany CR, Bäumler AJ. Dysbiosis: from fiction to function. Am J Physiol - Gastrointest Liver Physiol. 2019;317(5):G602–8. doi:10.1152/AJPGI.00230.2019.
   PubMed Web of Science ®Google Scholar
• Levy M, Kolodziejczyk AA, Thaiss CA, Elinav E. Dysbiosis and the immune system. Nat Rev Immunol. 2017;17(4):219–232. doi:10.1038/nri.2017.7.
   PubMed Web of Science ®Google Scholar
• Petersen C, Round JL. Defining dysbiosis and its influence on host immunity and disease. Cell Microbiol. 2014;16(7):1024–1033. doi:10.1111/cmi.12308.
   PubMed Web of Science ®Google Scholar
• Proctor L. What‗s next for the human microbiome? Nature. 2019;569(7758):623. doi:10.1038/d41586-019-01654-0.
   PubMed Web of Science ®Google Scholar
• Adolph TE, Meyer M, Schwärzler J, Mayr L, Grabherr F, Tilg H. The metabolic nature of inflammatory bowel diseases. Nat Rev Gastroenterol Hepatol. 2022;19(12):753–767. doi:10.1038/s41575-022-00658-y.
   PubMed Web of Science ®Google Scholar
• Uchiyama K, Haruyama Y, Shiraishi H, Katahira K, Abukawa D, Ishige T, Tajiri H, Uchida K, Uchiyama K, Washio M, et al. Association between passive smoking from the mother and pediatric crohn’s disease: a Japanese multicenter study. Int J Environ Res Public Health. 2020;17(8):2926. doi:10.3390/ijerph17082926.
   PubMed Web of Science ®Google Scholar
• Mahid SS, Minor KS, Stromberg AJ, Galandiuk S. Active and passive smoking in childhood is related to the development of inflammatory bowel disease. Inflamm Bowel Dis. 2007;13(4):431–438. doi:10.1002/ibd.20070.
   PubMed Web of Science ®Google Scholar
• Salih A, Widbom L, Hultdin J, Karling P. Smoking is associated with risk for developing inflammatory bowel disease including late onset ulcerative colitis: a prospective study. Scand J Gastroenterol. 2018;53(2):173–178. doi:10.1080/00365521.2017.1418904.
   PubMed Web of Science ®Google Scholar
• Troelsen FS, Jick S. Antibiotic use in childhood and adolescence and risk of inflammatory bowel disease: a case-control study in the UK clinical practice Research datalink. Inflamm Bowel Dis. 2020;26(3):440–447. doi:10.1093/ibd/izz137.
   PubMed Web of Science ®Google Scholar
• Virta L, Auvinen A, Helenius H, Huovinen P, Kolho KL. Association of repeated exposure to antibiotics with the development of pediatric crohn’s disease - a nationwide, register-based Finnish case-control study. Am J Epidemiol. 2012;175(8):775–784. doi:10.1093/aje/kwr400.
   PubMed Web of Science ®Google Scholar
• Korelitz BI. Role of nonsteroidal anti-inflammatory drugs in exacerbation of inflammatory bowel disease. J Clin Gastroenterol. 2016;50(2):97–98. doi:10.1097/MCG.0000000000000444.
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, Higuchi LM, Huang ES, Khalili H, Richter JM, Fuchs CS, Chan AT. Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis. Ann Intern Med. 2012;156(5):350–359. doi:10.7326/0003-4819-156-5-201203060-00007.
   PubMed Web of Science ®Google Scholar
• Khalili H, Higuchi LM, Ananthakrishnan AN, Richter JM, Feskanich D, Fuchs CS, Chan AT. Oral contraceptives, reproductive factors and risk of inflammatory bowel disease. Gut. 2013;62(8):1153–1159. doi:10.1136/gutjnl-2012-302362.
   PubMed Web of Science ®Google Scholar
• Ek WE, D’Amato M, Halfvarson J. The history of genetics in inflammatory bowel disease. Ann Gastroenterol. 2014;27:294–303.
   PubMedGoogle Scholar
• Van Limbergen J, Wilson DC, Satsangi J. The genetics of Crohn’s disease. Annu Rev Genom Hum Genet. 2009;10(1):89–116. doi:10.1146/annurev-genom-082908-150013.
   PubMedGoogle Scholar
• Thaiss CA, Zmora N, Levy M, Elinav E. The microbiome and innate immunity. Nature. 2016;535(7610):65–74. doi:10.1038/nature18847.
   PubMed Web of Science ®Google Scholar
• Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol. 2010;28:573–621. doi:10.1146/annurev-immunol-030409-101225.
   PubMed Web of Science ®Google Scholar
• Abraham C, Cho JH. T 2066. Bmj. 2009;361(21):2066–2078. doi:10.1056/NEJMra0804647.
   Google Scholar
• Cui X, Ye Z, Wang D, Yang Y, Jiao CH, Ma J, Tang N, Zhang H. Aryl hydrocarbon receptor activation ameliorates experimental colitis by modulating the tolerogenic dendritic and regulatory T cell formation. Cell & Biosci. 2022;12(1):1–13. doi:10.1186/s13578-022-00780-z.
   PubMed Web of Science ®Google Scholar
• Davidson M, Saiki J. A novel gut-restricted aryl hydrocarbon receptor agonist with activity in the dextran sodium sulfate colitis murine model. Inflamm Bowel Dis. 2023;29(Supplement_1):S3–S3. doi:10.1093/ibd/izac247.006.
   Google Scholar
• Petagna L, Antonelli A, Ganini C, Bellato V, Campanelli M, Divizia A, Efrati C, Franceschilli M, Guida AM, Ingallinella S, et al. Pathophysiology of Crohn’s disease inflammation and recurrence. Biol Direct. 2020;15(1):1–10. doi:10.1186/s13062-020-00280-5.
   PubMed Web of Science ®Google Scholar
• Cococcioni L, Panelli S, Varotto-Boccazzi I, Carlo D, Pistone D, Leccese G, Zuccotti GV, Comandatore F. Ibds and the pediatric age: their peculiarities and the involvement of the microbiota. Diges Liver Dis. 2021;53(1):17–25. doi:10.1016/j.dld.2020.10.033.
   Web of Science ®Google Scholar
• de Alencar Junior H, Paiotti APR, de Araújo Filho HB, Oshima CTF, Miszputen SJ, Ambrogini-Júnior O. The relationship between the commensal microbiota levels and Crohn’s disease activity. JGH Open. 2020;4(5):784–789. doi:10.1002/jgh3.12338.
   PubMed Web of Science ®Google Scholar
• Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn’s disease. Lancet. 2017;389(10080):1741–1755. doi:10.1016/S0140-6736(16)31711-1.
   PubMed Web of Science ®Google Scholar
• Hansen R, Russell RK, Reiff C, Louis P, McIntosh F, Berry SH, Mukhopadhya I, Bisset MW, Barclay AR, Bishop J, et al. Microbiota of de-novo pediatric IBD: increased faecalibacterium prausnitzii and reduced bacterial diversity in Crohn’s but not in ulcerative colitis. Am J Gastroenterol. 2012;107(12):1913–1922. doi:10.1038/ajg.2012.335.
   PubMed Web of Science ®Google Scholar
• Frank DN, St. Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA. 2007;104(34):13780–13785. doi:10.1073/pnas.0706625104.
   PubMed Web of Science ®Google Scholar
• Lewis JD, Chen EZ, Baldassano RN, Otley AR, Griffiths AM, Lee D, Bittinger K, Bailey A, Friedman E, Hoffmann C, et al. Inflammation, antibiotics, and diet as environmental stressors of the gut microbiome in pediatric Crohn’s disease. Cell Host & Microbe. 2015;18(4):489–500. doi:10.1016/j.chom.2015.09.008.
   PubMed Web of Science ®Google Scholar
• Gastroenterol WJ. Emerging therapeutic options in inflammatory bowel disease. Contents. 2021;9327(48):8242–8261).
   Google Scholar
• Ashton JJ, Gavin J, Beattie RM. Exclusive enteral nutrition in Crohn’s disease: evidence and practicalities. Clin Nutr. 2019;38(1):80–89. doi:10.1016/j.clnu.2018.01.020.
   PubMed Web of Science ®Google Scholar
• Heuschkel R, Pender S, Paintin M, Arnaud-Battandier F, Walker J, MacDonald T. Imbalance of stromelysin-1 and timp-1 mRNA and protein in the mucosal lesions of children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1999;28(5):557. doi:10.1097/00005176-199905000-00073.
   Google Scholar
• Xiao F, Gao X, Hu H, Le J, Chen Y, Shu X, Liang Z, Xu Y, Wang Y, Zhang T. Exclusive enteral nutrition exerts anti-inflammatory effects through modulating microbiota, bile acid metabolism, and immune activities. Nutr. 2022;14(21):4463. doi:10.3390/nu14214463.
   Google Scholar
• Weingarden AR, Vaughn BP. Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease. Gut Microbes. 2017;8(3):238–252. doi:10.1080/19490976.2017.1290757.
   PubMed Web of Science ®Google Scholar
• Khanna S, Raffals LE. The microbiome in Crohn’s disease: role in pathogenesis and role of microbiome replacement therapies. Gastroenterol Clin North Am. 2017;46(3):481–492. doi:10.1016/j.gtc.2017.05.004.
   PubMed Web of Science ®Google Scholar
• Gruszecka J, Filip R. Does anti-TNF-α therapy affect the bacteriological profile of specimens collected from perianal lesions? A retrospective analysis in patients with Crohn’s disease. Int J Environ Res Public Health. 2022;19(5):2892. doi:10.3390/ijerph19052892.
   PubMed Web of Science ®Google Scholar
• Fousekis FS, Theopistos VI, Tsianos KH, Katsanos EV, Christodoulou DK. Hepatobiliary manifestations and complications in inflammatory bowel disease: a review. Gastroenterol Res. 2018;11(2):83–94. doi:10.14740/gr990w.
   PubMed Web of Science ®Google Scholar
• Ledder O, Turner D. Antibiotics in IBD: still a role in the biological era? Inflamm Bowel Dis. 2018;24(9):1676–1688. doi:10.1093/ibd/izy067.
   PubMedGoogle Scholar
• Wilschanski M, Sherman P, Pencharz P, Davis L, Corey M, Griffiths A. Supplementary enteral nutrition maintains remission in paediatric Crohn’s disease. Gut. 1996;38(4):543–548. doi:10.1136/gut.38.4.543.
   PubMed Web of Science ®Google Scholar
• Levine A, Wine E, Assa A, Sigall Boneh R, Shaoul R, Kori M, Cohen S, Peleg S, Shamaly H, On A, et al. Crohn’s disease exclusion diet plus partial enteral nutrition induces sustained remission in a randomized controlled trial. Gastroenterol. 2019;157(2):440–450.e8. doi:10.1053/j.gastro.2019.04.021.
   PubMed Web of Science ®Google Scholar
• Hollister EB, Gao C, Versalovic J. Compositional and functional features of the gastrointestinal microbiome and their effects on human health. Gastroenterol. 2014;146(6):1449–1458. doi:10.1053/j.gastro.2014.01.052.
   PubMed Web of Science ®Google Scholar
• Arumugam M, Raes J, Pelletier E, Paslier D, Yamada T, Mende DR, Fernandes GR, Tap J, Bruls T, Batto JM, et al. Enterotypes of the human gut microbiome. Nature. 2011;473(7346):174–180. doi:10.1038/nature09944.
   PubMed Web of Science ®Google Scholar
• Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA. Diversity of the human intestinal microbial flora. Sci. 2005;308(5728):1635–1638. doi:10.1126/science.1110591.
   PubMed Web of Science ®Google Scholar
• Harrell L, Wang Y, Antonopoulos D, Young V, Lichtenstein L, Huang Y, Hanauer S, Chang E. Standard colonic lavage alters the natural state of mucosal-associated microbiota in the human colon. PLoS One. 2012;7(2):e32545. doi:10.1371/journal.pone.0032545.
   PubMed Web of Science ®Google Scholar
• Maharshak N, Ringel Y, Katibian D, Lundqvist A, Sartor RB, Carroll IM, Ringel-Kulka T. Fecal and mucosa-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Dig Dis Sci. 2018;63(7):1890–1899. doi:10.1007/s10620-018-5086-4.
   PubMed Web of Science ®Google Scholar
• Klymiuk I, Singer G, Castellani C, Trajanoski S, Obermüller B, Till H. Characterization of the luminal and mucosa-associated microbiome along the gastrointestinal tract: results from surgically treated preterm infants and a murine model. Nutr. 2021;13(3):1030. doi:10.3390/nu13031030.
   Google Scholar
• Kashiwagi S, Naito Y, Inoue R, Takagi T, Nakano T, Inada Y, Fukui A, Katada K, Mizushima K, Kamada K, et al. Mucosa-associated microbiota in the gastrointestinal tract of healthy Japanese subjects. Digest. 2020;101(2):107–120. doi:10.1159/000496102.
   PubMed Web of Science ®Google Scholar
• Kim H, Sitarik AR, Woodcroft K, Johnson CC, Zoratti E. Birth mode, breastfeeding, pet exposure, and antibiotic use: associations with the gut microbiome and sensitization in children. Curr Allergy Asthma Rep. 2019;19(4). doi:10.1007/s11882-019-0851-9.
   Web of Science ®Google Scholar
• Haro C, Rangel-Zúñiga OA, Alcalá-Díaz JF, Gómez-Delgado F, Pérez-Martínez P, Delgado-Lista J, Quintana-Navarro GM, Landa BB, Navas-Cortés JA, Tena-Sempere M, et al. Intestinal microbiota is influenced by gender and body mass index. PLoS One. 2016;11(5):1–16. doi:10.1371/journal.pone.0154090.
   Web of Science ®Google Scholar
• Koliada A, Syzenko G, Moseiko V, Budovska L, Puchkov K, Perederiy V, Gavalko Y, Dorofeyev A, Romanenko M, Tkach S, et al. Association between body mass index and Firmicutes/Bacteroidetes ratio in an adult Ukrainian population. BMC Microbiol. 2017;17(1):4–9. doi:10.1186/s12866-017-1027-1.
   PubMedGoogle Scholar
• Yun Y, Kim HN, Kim SE, Heo SG, Chang Y, Ryu S, Shin H, Kim H-L. Comparative analysis of gut microbiota associated with body mass index in a large Korean cohort. BMC Microbiol. 2017;17(1):1–9. doi:10.1186/s12866-017-1052-0.
   PubMedGoogle Scholar
• Azad MB, Konya T, Persaud RR, Guttman DS, Chari RS, Field CJ, Sears MR, Mandhane PJ, Turvey SE, Subbarao P, et al. Impact of maternal intrapartum antibiotics, method of birth and breastfeeding on gut microbiota during the first year of life: a prospective cohort study. BJOG: Int J Obstet Gy. 2016;123(6):983–993. doi:10.1111/1471-0528.13601.
   PubMed Web of Science ®Google Scholar
• Ringel-Kulka T, Cheng J, Ringel Y, Salojärvi J, Carroll I, Palva A, de Vos WM, Satokari R. Intestinal microbiota in healthy U.S. Young children and adults—a high throughput microarray analysis. PLoS One. 2013;8(5):e64315. doi:10.1371/journal.pone.0064315.
   PubMed Web of Science ®Google Scholar
• Claesson MJ, Cusack S, O’Sullivan O, Greene-Diniz R, De Weerd H, Flannery E, Marchesi JR, Falush D, Dinan T, Fitzgerald G, et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci USA. 2011;108(SUPPL. supplement_1):4586–4591. doi:10.1073/pnas.1000097107.
   PubMedGoogle Scholar
• Biagi E, Franceschi C, Rampelli S, Severgnini M, Ostan R, Turroni S, Consolandi C, Quercia S, Scurti M, Monti D, et al. Gut microbiota and extreme longevity. Curr Biol. 2016;26(11):1480–1485. doi:10.1016/j.cub.2016.04.016.
   PubMed Web of Science ®Google Scholar
• Drago L, Toscano M, Rodighiero V, De Vecchi E, Mogna G. Cultivable and pyrosequenced fecal microflora in centenarians and young subjects. J Clin Gastroenterol. 2012;46(SUPPL. 1):81–84. doi:10.1097/MCG.0b013e3182693982.
   Google Scholar
• Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol. 2018;11(1):1–10. doi:10.1007/s12328-017-0813-5.
   PubMed Web of Science ®Google Scholar
• Dominguez-Bello MG, Godoy-Vitorino F, Knight R, Blaser MJ. Role of the microbiome in human development. Gut. 2019;68(6):1108–1114. doi:10.1136/gutjnl-2018-317503.
   PubMed Web of Science ®Google Scholar
• Koboziev I, Karlsson F, Grisham MB. Gut-associated lymphoid tissue, T cell trafficking, and chronic intestinal inflammation. Ann N Y Acad Sci. 2010;1207(SUPPL.1):86–93. doi:10.1111/j.1749-6632.2010.05711.x.
   PubMedGoogle Scholar
• Agace WW. T-cell recruitment to the intestinal mucosa. Trends Immunol. 2008;29(11):514–522. doi:10.1016/j.it.2008.08.003.
   PubMed Web of Science ®Google Scholar
• Torres J, Hu J, Seki A, Eisele C, Nair N, Huang R, Tarassishin L, Jharap B, Cote-Daigneault J, Mao Q, et al. Infants born to mothers with IBD present with altered gut microbiome that transfers abnormalities of the adaptive immune system to germ-free mice. Gut. 2020;69(1):42–51. doi:10.1136/gutjnl-2018-317855.
   PubMed Web of Science ®Google Scholar
• Kim ES, Tarassishin L, Eisele C, Barre A, Nair N, Rendon A, Hawkins K, Debebe A, White S, Thjømøe A, et al. Longitudinal changes in Fecal calprotectin levels among pregnant women with and without inflammatory bowel disease and their babies. Gastroenterol. 2021;160(4):1118–1130.e3. doi:10.1053/J.GASTRO.2020.11.050.
   PubMed Web of Science ®Google Scholar
• Gevers D, Kugathasan S, Denson LA, Vázquez-Baeza Y, Van Treuren W, Ren B, Schwager E, Knights D, Song S, Yassour M, et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host & Microbe. 2014;15(3):382–392. doi:10.1016/j.chom.2014.02.005.
   PubMed Web of Science ®Google Scholar
• Kansal S, Catto-Smith AG, Boniface K, Thomas S, Cameron DJ, Oliver M, Alex G, Kirkwood C, Wagner J. The microbiome in paediatric Crohn’s disease—a longitudinal, prospective, single-centre study. J Crohns Colitis. 2019;13(8):1044–1054. doi:10.1093/ecco-jcc/jjz016.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Nishida A, Fujimoto T, Fujii M, Shioya M, Imaeda H, Inatomi O, Bamba S, Andoh A, Sugimoto M. Reduced abundance of butyrate-producing bacteria species in the Fecal microbial community in Crohn’s disease. Digestion. 2016;93(1):59–65. doi:10.1159/000441768.
   PubMed Web of Science ®Google Scholar
• Miquel S, Martín R, Rossi O, Bermúdez-Humarán LG, Chatel JM, Sokol H, Thomas M, Wells JM, Langella P. Faecalibacterium prausnitzii and human intestinal health. Curr Opin Microbiol. 2013;16(3):255–261. doi:10.1016/j.mib.2013.06.003.
   PubMed Web of Science ®Google Scholar
• Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet J-P, Corthier G, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008;105(43):16731–16736. doi:10.1073/pnas.0804812105.
   PubMed Web of Science ®Google Scholar
• Caparrós E, Wiest R, Scharl M, Rogler G, Gutiérrez Casbas A, Yilmaz B, Wawrzyniak M, Francés R. Dysbiotic microbiota interactions in Crohn’s disease. Gut Microbes. 2021;13(1):1–19. doi:10.1080/19490976.2021.1949096.
   Web of Science ®Google Scholar
• Pascal V, Pozuelo M, Borruel N, Casellas F, Campos D, Santiago A, Martinez X, Varela E, Sarrabayrouse G, Machiels K, et al. A microbial signature for Crohn’s disease. Gut. 2017;66(5):813–822. doi:10.1136/gutjnl-2016-313235.
   PubMed Web of Science ®Google Scholar
• Zhao H, Xu H, Chen S, He J, Zhou Y, Nie Y. Systematic review and meta-analysis of the role of faecalibacterium prausnitzii alteration in inflammatory bowel disease. J Gastroenterol Hepatol. 2021;36(2):320–328. doi:10.1111/jgh.15222.
   PubMedGoogle Scholar
• Barnich N, Aguirre JE, Reinecker HC, Xavier R, Podolsky DK. Membrane recruitment of NOD2 in intestinal epithelial cells is essential for nuclear factor-ΚB activation in muramyl dipeptide recognition. J Cell Biol. 2005;170(1):21–26. doi:10.1083/jcb.200502153.
   PubMed Web of Science ®Google Scholar
• Wehkamp J, Stange EF. An update review on the Paneth cell as key to ileal Crohn’s disease. Front Immunol. 2020;11(April). doi:10.3389/fimmu.2020.00646.
   Google Scholar
• Ashton JJ, Seaby EG, Beattie RM, Ennis S. NOD2 in Crohn’s disease—unfinished business. J Crohns Colitis. 2023;17(3):450–458. doi:10.1093/ecco-jcc/jjac124.
   PubMed Web of Science ®Google Scholar
• Gao P, Liu H, Huang H, Sun Y, Jia B, Hou B, Zhou X, Strober W, Zhang F. The Crohn disease-associated ATG16L1T300A polymorphism regulates inflammatory responses by modulating TLR- and NLR-mediated signaling. Autophagy. 2022;18(11):2561–2575. doi:10.1080/15548627.2022.2039991.
   PubMed Web of Science ®Google Scholar
• Martinez-Medina M, Aldeguer X, Lopez-Siles M, González-Huix F, López-Oliu C, Dahbi G, Blanco JE, Blanco J, Garcia-Gil JL, Darfeuille-Michaud A. Molecular diversity of Escherichia coli in the human gut: new ecological evidence supporting the role of adherent-invasive E. coli (AIEC) in Crohnʼs disease. Inflamm Bowel Dis. 2009;15(6):872–882. doi:10.1002/ibd.20860.
   PubMed Web of Science ®Google Scholar
• Jiang W, Su J, Zhang X, Cheng X, Zhou J, Shi R, Zhang H. Elevated levels of Th17 cells and Th17-related cytokines are associated with disease activity in patients with inflammatory bowel disease. Inflamm Res. 2014;63(11):943–950. doi:10.1007/s00011-014-0768-7.
   PubMed Web of Science ®Google Scholar
• Mitsuyama K, Niwa M, Takedatsu H, Yamasaki H, Kuwaki K, Yoshioka S, Yamauchi R, Fukunaga S, Torimura T. Antibody markers in the diagnosis of inflammatory bowel disease. World J Gastroenterol. 2016;22(3):1304–1310. doi:10.3748/wjg.v22.i3.1304.
   PubMed Web of Science ®Google Scholar
• Wang JQ, Huang Y. Serological markers of inflammatory bowel disease. World Chinese J Dig. 2013;21(36):4110–4115. doi:10.11569/wcjd.v21.i36.4110.
   Google Scholar
• Zimmerman L, Bousvaros A. The pharmacotherapeutic management of pediatric Crohn’s disease. Expert Opin Pharmacother. 2019;20(17):2161–2168. doi:10.1080/14656566.2019.1659778.
   PubMed Web of Science ®Google Scholar
• Akobeng AK. Crohn’s disease: current treatment options. Arch Dis Child. 2008;93(9):787–792. doi:10.1136/adc.2007.128751.
   PubMed Web of Science ®Google Scholar
• Schwermer M, Fetz K, Längler A, Ostermann T, Zuzak TJ. Complementary, alternative, integrative and dietary therapies for children with Crohn’s disease – a systematic review. Complement Ther Med. 2020;52(June):102493. doi:10.1016/j.ctim.2020.102493.
   PubMedGoogle Scholar
• Brookes MJ, Green JRB. Maintenance of remission in Crohn’s disease: current and emerging therapeutic options. Drugs. 2004;64(10):1069–1089. doi:10.2165/00003495-200464100-00004.
   PubMed Web of Science ®Google Scholar
• Bradford K, Shih DQ. Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. World J Gastroenterol. 2011;17(37):4166–4173. doi:10.3748/wjg.v17.i37.4166.
   PubMed Web of Science ®Google Scholar
• Dubinsky MC. Azathioprine 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol. 2004;2(9):731–743. doi:10.1016/S1542-3565(04)00344-1.
   PubMed Web of Science ®Google Scholar
• Cronstein BN. The mechanism of action of methotrexate. Rheum Dis Clin North Am. 1997;23(4):739–755. doi:10.1016/S0889-857X(05)70358-6.
   PubMed Web of Science ®Google Scholar
• Ludvigsson JF. Antibiotic use and inflammatory bowel disease: number needed to harm? Gut. 2023;(0):gutjnl-2023–329575. doi:10.1136/gutjnl-2023-329575.
   Google Scholar
• Weisband YL. Association of antibiotic use with durability of biologic agents in inflammatory bowel disease. A Report From The Epi-IIRN. 2023;jjad070(April):1–8.
   Google Scholar
• Bogatic D, Bryant RV, Lynch KD, Costello SP. Systematic review: microbial manipulation as therapy for primary sclerosing cholangitis. Aliment Pharmacol Ther. 2023;57(1):23–36. doi:10.1111/apt.17251.
   PubMed Web of Science ®Google Scholar
• Lafferty L, Tuohy M, Carey A, Sugrue S, Hurley M, Hussey S. Outcomes of exclusive enteral nutrition in paediatric Crohn’s disease. Eur J Clin Nutr. 2017;71(2):185–191. doi:10.1038/ejcn.2016.210.
   PubMed Web of Science ®Google Scholar
• Grover Z, Lewindon P. Two-year outcomes after exclusive enteral nutrition induction are superior to corticosteroids in pediatric Crohn’s disease treated early with thiopurines. Dig Dis Sci. 2015;60(10):3069–3074. doi:10.1007/s10620-015-3722-9.
   PubMed Web of Science ®Google Scholar
• Dunn KA, Moore-Connors J, Macintyre B, Stadnyk AW, Thomas NA, Noble A, Mahdi G, Rashid M, Otley AR, Bielawski JP, et al. Early changes in microbial community structure are associated with sustained remission after nutritional treatment of pediatric Crohnʼs disease. Inflamm Bowel Dis. 2016;22(12):2853–2862. doi:10.1097/MIB.0000000000000956.
   PubMed Web of Science ®Google Scholar
• Lv Y, Lou Y, Liu A, Cheng Q, Yang G, Xu C, Luo Y, Lou J, Yu J, Fang Y, et al. The impact of exclusive enteral nutrition on the gut microbiome and bile acid metabolism in pediatric Crohn’s disease. Clin Nutr. 2023;42(2):116–128. doi:10.1016/J.CLNU.2022.11.018.
   PubMed Web of Science ®Google Scholar
• Verburgt CM, Dunn KA, Ghiboub M, Lewis JD, Wine E, Sigall Boneh R, Gerasimidis K, Shamir R, Penny S, Pinto DM, et al. Successful dietary therapy in paediatric Crohn’s disease is associated with shifts in bacterial dysbiosis and inflammatory metabotype towards healthy controls. J Crohns Colitis. 2023;17(1):61–72. doi:10.1093/ecco-jcc/jjac105.
   PubMed Web of Science ®Google Scholar
• Zhuang X, Tian Z, Feng R, Li M, Li T, Zhou G, Qiu Y, Chen B, He Y, Chen M, et al. Fecal microbiota alterations associated with clinical and endoscopic response to infliximab therapy in crohn’s disease. Inflamm Bowel Dis. 2020;26(11):1636–1647. doi:10.1093/ibd/izaa253.
   PubMed Web of Science ®Google Scholar
• Wang A, Zhang Z, Ding Q, Yang Y, Bindelle J, Ran C, Zhou Z. Intestinal cetobacterium and acetate modify glucose homeostasis via parasympathetic activation in zebrafish. Gut Microbes. 2021;13(1):1–15. doi:10.1080/19490976.2021.1900996.
   PubMed Web of Science ®Google Scholar
• Doherty MK, Ding T, Koumpouras C, Telesco SE, Monast C, Das A, Brodmerkel C, Schloss PD. Fecal microbiota signatures are associated with response to ustekinumab therapy among crohn’s disease patients. MBio. 2018;9(2). doi:10.1128/mBio.02120-17.
   PubMed Web of Science ®Google Scholar
• González-Torres L, Moreno-Álvarez A, Fernández-Lorenzo AE, Leis R, Solar-Boga A. The role of partial enteral nutrition for induction of remission in Crohn’s disease: a systematic review of controlled trials. Nutrients. 2022;14(24):5263. doi:10.3390/nu14245263.
   PubMed Web of Science ®Google Scholar
• Yanai H, Levine A, Hirsch A, Boneh RS, Kopylov U, Eran HB, Cohen NA, Ron Y, Goren I, Leibovitzh H, et al. The Crohn’s disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn’s disease (CDED-AD): an open-label, pilot, randomised trial. Lancet Gastroenterol Hepatol. 2022;7(1):49–59. doi:10.1016/S2468-1253(21)00299-5.
   PubMed Web of Science ®Google Scholar
• Hart L, Verburgt CM, Wine E, Zachos M, Poppen A, Chavannes M, Van Limbergen J, Pai N. Nutritional therapies and their influence on the intestinal microbiome in pediatric inflammatory bowel disease. Nutr. 2022;14(1):4–22. doi:10.3390/nu14010004.
   Google Scholar
• Ding Z, Ninan K, Johnston BC, Moayyedi P, Sherlock M, Zachos M. Microbiota signatures and mucosal healing in the use of enteral nutrition therapy versus corticosteroids for the treatment of children with Crohn’s disease: a systematic review and meta-analysis. Br J Nutr. 2023;16–19. doi:10.1017/S0007114523000405.
   Web of Science ®Google Scholar
• Melton SL, Taylor KM, Gibson PR, Halmos EP. Review article: mechanisms underlying the effectiveness of exclusive enteral nutrition in Crohn’s disease. Aliment Pharmacol Ther. 2023 October;57(9):932–947. doi:10.1111/apt.17451.
   PubMed Web of Science ®Google Scholar
• Gkikas K, Logan M, Nichols B, Ijaz UZ, Clark CM, Svolos V, Gervais L, Duncan H, Garrick V, Curtis L, et al. Dietary triggers of gut inflammation following exclusive enteral nutrition in children with Crohn’s disease: a pilot study. BMC Gastroenterol. 2021;21(1):1–11. doi:10.1186/s12876-021-02029-4.
   PubMed Web of Science ®Google Scholar
• Gerasimidis K, Gkikas K, Stewart C, Neelis E, Svolos V. Microbiome and paediatric gut diseases. Arch Dis Child. 2022;107(9):784–789. doi:10.1136/archdischild-2020-320875.
   PubMed Web of Science ®Google Scholar
• Pigneur B, Lepage P, Mondot S, Schmitz J, Goulet O, Doré J, Ruemmele FM. Mucosal healing and bacterial composition in response to enteral nutrition vs steroid-based induction therapy—A randomised prospective clinical trial in children with Crohn’s disease. J Crohn’s Colitis. 2019;13(7):846–855. doi:10.1093/ecco-jcc/jjy207.
   Google Scholar
• Soo J, Malik BA, Turner JM, Persad R, Wine E, Siminoski K, Huynh HQ. Use of exclusive enteral nutrition is just as effective as corticosteroids in newly diagnosed pediatric Crohn’s disease. Dig Dis Sci. 2013;58(12):3584–3591. doi:10.1007/s10620-013-2855-y.
   PubMed Web of Science ®Google Scholar
• Narula N, Dhillon A, Zhang D, Sherlock ME, Tondeur M, Zachos M. Enteral nutritional therapy for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2018;2018(4). doi:10.1002/14651858.CD000542.pub3.
   Google Scholar
• Morain CO, Segal AW, Levi AJ. Elemental diet as primary treatment of acute Crohn’s disease: a controlled trial. Br Med J. 1984;288(6434):1859–1862. doi:10.1136/bmj.288.6434.1859.
   PubMedGoogle Scholar
• Okada M, Yao T, Yamamoto T, Takenaka K, Imamura K, Maeda KF, Fujita K. Controlled trial comparing an elemental diet with prednisolone in the treatment of active Crohn’s disease. Hepatogastroenterol. 1990;37:72–80.
   PubMedGoogle Scholar
• Xiang L, Ding X, Li Q, Wu X, Dai M, Long C, He Z, Cui B, Zhang F. Efficacy of faecal microbiota transplantation in Crohn’s disease: a new target treatment? Microb Biotechnol. 2020;13(3):760–769. doi:10.1111/1751-7915.13536.
   PubMed Web of Science ®Google Scholar
• Jarmo O, Veli-Jukka A, Eero M. Treatment of clostridioides (clostridium) difficile infection. Ann Med. 2020;52(1–2):12–20. doi:10.1080/07853890.2019.1701703.
   PubMed Web of Science ®Google Scholar
• Li P, Zhang T, Xiao Y, Tian L, Cui B, Ji G, Liu YY, Zhang F. Timing for the second fecal microbiota transplantation to maintain the long-term benefit from the first treatment for Crohn’s disease. Appl Microbiol Biotechnol. 2019;103(1):349–360. doi:10.1007/s00253-018-9447-x.
   PubMed Web of Science ®Google Scholar
• Vaughn BP, Vatanen T, Allegretti JR, Bai A, Xavier RJ, Korzenik J, Gevers D, Ting A, Robson SC, Moss AC. Increased intestinal microbial diversity following Fecal microbiota transplant for active Crohnʼs disease. Inflamm Bowel Dis. 2016;22(9):2182–2190. doi:10.1097/MIB.0000000000000893.
   PubMed Web of Science ®Google Scholar
• Yang Z, Bu C, Yuan W, Shen Z, Quan Y, Wu S, Zhu C, Wang X. Fecal microbiota transplant via endoscopic delivering through small intestine and colon: no difference for Crohn’s disease. Dig Dis Sci. 2020;65(1):150–157. doi:10.1007/s10620-019-05751-y.
   PubMed Web of Science ®Google Scholar
• Suskind DL, Brittnacher MJ, Wahbeh G, Shaffer ML, Hayden HS, Qin X, Singh N, Damman CJ, Hager KR, Nielson H, et al. Fecal microbial transplant effect on clinical outcomes and Fecal microbiome in active Crohnʼs disease. Inflamm Bowel Dis. 2015;21(3):556–563. doi:10.1097/MIB.0000000000000307.
   PubMed Web of Science ®Google Scholar
• Wang H, Cui B, Li Q, Ding X, Li P, Zhang T, Yang X, Ji G, Zhang F. The safety of fecal microbiota transplantation for Crohn’s disease: findings from a long-term study. Adv Ther. 2018;35(11):1935–1944. doi:10.1007/s12325-018-0800-3.
   PubMed Web of Science ®Google Scholar
• Pai N, Popov J, Hill L, Hartung E. Protocol for a double-blind, randomised, placebo-controlled pilot study for assessing the feasibility and efficacy of faecal microbiota transplant in a paediatric Crohn’s disease population: PediCRaFT trial. BMJ Open. 2019;9(11):1–11. doi:10.1136/bmjopen-2019-030120.
   PubMedGoogle Scholar
• Aardoom MA, Veereman G, de Ridder L. A review on the use of anti-TNF in children and adolescents with inflammatory bowel disease. Int J Mol Sci. 2019;20(10). doi:10.3390/ijms20102529.
   PubMed Web of Science ®Google Scholar
• Balzola F, Cullen G, Ho GT, Russell RK, Wehkamp J. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease: commentary. Inflamm Bowel Dis Monit. 2012;13(2):69. doi:10.1056/NEJMoa1203572.
   Google Scholar
• Balzola F, Cullen G, Ho GT, Russell R. Vedolizumab as induction and maintenance therapy for Crohn’s disease: commentary. Inflamm Bowel Dis Monit. 2014;14(2):55–56. doi:10.1056/NEJMoa1215739.
   Google Scholar
• Jongsma MME, Aardoom MA, Cozijnsen MA, Van Pieterson M, De Meij T, Groeneweg M, Norbruis OF, Wolters VM, van Wering HM, Hojsak I, et al. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial. Gut. 2022;71(1):34–42. doi:10.1136/gutjnl-2020-322339.
   PubMed Web of Science ®Google Scholar
• Parigi TL, Iacucci M, Ghosh S. Blockade of IL-23: What is in the pipeline? J Crohn’s Colitis. 2022;16(Supplement_2):ii64–ii72. doi:10.1093/ecco-jcc/jjab185.
   Google Scholar
• Sandborn WJ, Rebuck R, Wang Y, Zou B, Adedokun OJ, Gasink C, Sands BE, Hanauer SB, Targan S, Ghosh S, et al. Five-year efficacy and safety of ustekinumab treatment in Crohn’s disease: The IM-UNITI trial. Clin Gastroenterol Hepatol. 2022;20(3):578–590.e4. doi:10.1016/j.cgh.2021.02.025.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, et al. Risankizumab as induction therapy for Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399(10340):2015–2030. doi:10.1016/S0140-6736(22)00467-6.
   PubMed Web of Science ®Google Scholar
• Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022;399(10340):2031–2046. doi:10.1016/S0140-6736(22)00466-4.
   PubMed Web of Science ®Google Scholar
• Thia KT, Mahadevan U, Feagan BG, Wong C, Cockeram A, Bitton A, Bernstein CN, Sandborn WJ. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohnʼs disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2009;15(1):17–24. doi:10.1002/ibd.20608.
   PubMed Web of Science ®Google Scholar
• Breton J, Tanes C, Tu V, Albenberg L, Rowley S, Devas N, Hwang R, Kachelries K, Wu GD, Baldassano RN, et al. A microbial signature for paediatric perianal Crohn’s disease. J Crohns Colitis. 2022;16(8):1281–1292. doi:10.1093/ecco-jcc/jjac032.
   PubMed Web of Science ®Google Scholar
• Tabibian JH, Weeding E, Jorgensen RA, Petz JL, Keach JC, Talwalkar JA, Lindor KD. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther. 2013;37(6):604–612. doi:10.1111/apt.12232.
   PubMed Web of Science ®Google Scholar
• Nitzan O, Elias M, Peretz A, Saliba W. Role of antibiotics for treatment of inflammatory bowel disease. World J Gastroenterol. 2016;22(3):1078–1087. doi:10.3748/wjg.v22.i3.1078.
   PubMed Web of Science ®Google Scholar
• Wise PE, Schwartz DA. Management of perianal Crohn’s disease. Clin Gastroenterol Hepatol. 2006;4(4):426–430. doi:10.1016/j.cgh.2006.02.001.
   PubMed Web of Science ®Google Scholar
• Elliott PR, Moore GTC, Bell SJ, Connell WR. Severe recurrent Crohn’s disease of the ileocolonic anastomosis disappearing completely with antibacterial therapy [2]. Gut. 2005;54(12):1818–1819. doi:10.1136/gut.2005.078568.
   PubMed Web of Science ®Google Scholar
• Levine A, Turner D. Combined azithromycin and metronidazole therapy is effective in inducing remission in pediatric Crohn’s disease. J Crohn’s Colitis. 2011;5(3):222–226. doi:10.1016/j.crohns.2011.01.006.
   Google Scholar
• Strong SA. Perianal Crohn’s disease. Semin Pediatr Surg. 2007;16(3):185–193. doi:10.1053/j.sempedsurg.2007.04.007.
   PubMedGoogle Scholar
• Park SK, Kim KJ, Lee SO, Yang DH, Jung KW, Duk Ye B, Byeon JS, Myung SJ, Yang SK, Kim JH, et al. Ciprofloxacin usage and bacterial resistance patterns in Crohn’s disease patients with abscesses. J Clin Gastroenterol. 2014;48(8):703–707. doi:10.1097/MCG.0000000000000024.
   PubMed Web of Science ®Google Scholar
• Rahimpour S, Nasiri-Toosi M, Khalili H, Daryani NE, Taromlou MKN, Azizi Z. A triple blinded, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: a pilot study. J Gastrointest Liver Dis. 2016;25(4):457–464. doi:10.15403/jgld.2014.1121.254.rah.
   PubMed Web of Science ®Google Scholar
• Chandok N, Hirschfield GM. Management of primary sclerosing cholangitis: conventions and controversies. Can J Gastroenterol. 2012;26(5):261–268. doi:10.1155/2012/426430.
   PubMed Web of Science ®Google Scholar
• Kucharska M, Daniluk U, Kwiatek-Średzińska KA, Wasilewska N, Filimoniuk A, Jakimiec P, Zdanowicz K, Lebensztejn D. Hepatobiliary manifestations of inflammatory bowel disease in children. Clin Exp Hepatol. 2019;5(3):203–209. doi:10.5114/ceh.2019.87632.
   PubMed Web of Science ®Google Scholar
• Ni Mhuircheartaigh JM, Lee KS, Curry MP, Pedrosa I, Mortele KJ. Early peribiliary hyperenhancement on MRI in patients with primary sclerosing cholangitis: significance and Association with the mayo risk score. Abdom Radiol. 2017;42(1):152–158. doi:10.1007/s00261-016-0847-z.
   PubMed Web of Science ®Google Scholar
• Khoshpouri P, Ameli S, Ghasabeh MA, Pandey A, Zarghampour M, Varzaneh FN, Jacob A, Pandey P, Luo Y, Kamel IR, et al. Correlation between quantitative liver and spleen volumes and disease severity in primary sclerosing cholangitis as determined by mayo risk score. Eur J Radiol. 2018;108:254–260. doi:10.1016/J.EJRAD.2018.10.006.
   PubMed Web of Science ®Google Scholar
• Turner D, Bishai J, Reshef L, Abitbol G, Focht G, Marcus D, Ledder O, Lev-Tzion R, Orlanski-Meyer E, Yerushalmi B, et al. Antibiotic cocktail for pediatric acute severe colitis and the microbiome: the PRASCO randomized controlled trial. Inflamm Bowel Dis. 2020;26(11):1733–1742. doi:10.1093/ibd/izz298.
   PubMed Web of Science ®Google Scholar
• Guslandi M. Rifaximin in the treatment of inflammatory bowel disease. World J Gastroenterol. 2011;17(42):4643–4646. doi:10.3748/wjg.v17.i42.4643.
   PubMed Web of Science ®Google Scholar
• Muniyappa P, Gulati R, Mohr F, Hupertz V. Use and safety of rifaximin in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2009;49(4):400–404. doi:10.1097/MPG.0b013e3181a0d269.
   PubMed Web of Science ®Google Scholar
• Lopetuso LR, Napoli M, Rizzatti G, Gasbarrini A. The intriguing role of rifaximin in gut barrier chronic inflammation and in the treatment of Crohn’s disease. Expert Opin Investig Drugs. 2018;27(6):543–551. doi:10.1080/13543784.2018.1483333.
   PubMed Web of Science ®Google Scholar
• Maccaferri S, Vitali B, Klinder A, Kolida S, Ndagijimana M, Laghi L, Calanni F, Brigidi P, Gibson GR, Costabile A, et al. Rifaximin modulates the colonic microbiota of patients with Crohn’s disease: an in vitro approach using a continuous culture colonic model system. J Antimicrob Chemother. 2010;65(12):2556–2565. doi:10.1093/jac/dkq345.
   PubMed Web of Science ®Google Scholar
• Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Marshall JK, Talley NJ, Moayyedi P. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):661–673. doi:10.1038/ajg.2011.72.
   PubMed Web of Science ®Google Scholar
• Mishima Y, Sartor RB. Manipulating resident microbiota to enhance regulatory immune function to treat inflammatory bowel diseases. J Gastroenterol. 2020;55(1):4–14. doi:10.1007/s00535-019-01618-1.
   PubMed Web of Science ®Google Scholar
• Eindor-Abarbanel A, Healey GR, Jacobson K. Therapeutic advances in gut microbiome modulation in patients with inflammatory bowel disease from pediatrics to adulthood. Int J Mol Sci. 2021;22(22). doi:10.3390/ijms222212506.
   PubMed Web of Science ®Google Scholar
• Assar S, Nosratabadi R, Khorramdel Azad H, Masoumi J, Mohamadi M, Hassanshahi G. A review of immunomodulatory effects of fluoroquinolones. Immunol Invest. 2021;50(8):1007–1026. doi:10.1080/08820139.2020.1797778.
   PubMed Web of Science ®Google Scholar
• Sprockett D, Fischer N, Boneh RS, Turner D, Kierkus J, Sladek M, Escher JC, Wine E, Yerushalmi B, Dias JA, et al. Treatment-specific composition of the gut microbiota is associated with disease remission in a pediatric crohn’s disease cohort. Inflamm Bowel Dis. 2019;25(12):1927–1938. doi:10.1093/ibd/izz130.
   PubMed Web of Science ®Google Scholar